Shunchang Jiao

机构：Sinovac Biotech, Chinese PLA General Hospital, Chinese General Hospital College of Nursing and Liberal Arts · ORCID：0000-0001-9184-082X

发表论文 212 篇 · 总被引 5107 次 · h-index 34

代表论文

• First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial (2024 · The Lancet Respiratory Medicine · 被引 58)
• Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
• CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival (2024 · OncoImmunology · 被引 20)
• Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma via network pharmacology and experimental validation (2022 · Frontiers in Pharmacology · 被引 12)
• The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy as a neoadjuvant therapy for esophageal squamous cell carcinoma (2023 · Translational Oncology · 被引 11)
• LBA40 Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) (2024 · Annals of Oncology · 被引 10)